David Y Graham1, Hong Lu2,3, Maria Pina Dore4. 1. Department of Medicine, Michael E. DeBakey VAMC and Baylor College of Medicine, Houston, Texas. 2. GI Division, Ren Ji Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai Institution of Digestive Disease, Shanghai, China. 3. Key Laboratory of Gastroenterology & Hepatology, Ministry of Health, Shanghai, China. 4. Dipartimento di Scienze Mediche, Chirurgiche e Sperimentali, Clinica Medica, University of Sassari, Sassari, Italy.
Abstract
BACKGROUND: Helicobacter pylori treatment recommendations often recommend use of double-dose PPI or greater. This is confusing because PPIs very markedly in relative potency such that a double dose of one may not even be equivalent to the single dose of another. OBJECTIVE: To relate the concept of double-dose to specific amounts of the different PPIs METHODS: We used data standardizing PPI potency in terms of the duration of intragastric pH >4/24 hours (pH4-time) to rank PPIs. Relative potency varies from 4.5 mg omeprazole equivalents (20 mg pantoprazole) to 72 mg omeprazole equivalents (40 mg rabeprazole). RESULTS: We defined PPI dosing for H. pylori therapy as low dose (eg, approximately 20 mg omeprazole equivalents, b.i.d.), high or double dose as approximately 40 mg omeprazole equivalents, b.i.d.) and high dose as approximately 60 mg omeprazole equivalents, b.i.d.). For example, standard double dose PPI would thus be 40 mg of omeprazole, 20 mg of esomeprazole or rabeprazole, 45 mg of lansoprazole, or 120 mg of pantoprazole each given b.i.d. CONCLUSIONS: Simply doubling the dose of any PPI achieves markedly different effects on pH4-time. However, PPIs can be used interchangeably and cost effectively based on their omeprazole equivalency.
BACKGROUND:Helicobacter pylori treatment recommendations often recommend use of double-dose PPI or greater. This is confusing because PPIs very markedly in relative potency such that a double dose of one may not even be equivalent to the single dose of another. OBJECTIVE: To relate the concept of double-dose to specific amounts of the different PPIs METHODS: We used data standardizing PPI potency in terms of the duration of intragastric pH >4/24 hours (pH4-time) to rank PPIs. Relative potency varies from 4.5 mg omeprazole equivalents (20 mg pantoprazole) to 72 mg omeprazole equivalents (40 mg rabeprazole). RESULTS: We defined PPI dosing for H. pylori therapy as low dose (eg, approximately 20 mg omeprazole equivalents, b.i.d.), high or double dose as approximately 40 mg omeprazole equivalents, b.i.d.) and high dose as approximately 60 mg omeprazole equivalents, b.i.d.). For example, standard double dose PPI would thus be 40 mg of omeprazole, 20 mg of esomeprazole or rabeprazole, 45 mg of lansoprazole, or 120 mg of pantoprazole each given b.i.d. CONCLUSIONS: Simply doubling the dose of any PPI achieves markedly different effects on pH4-time. However, PPIs can be used interchangeably and cost effectively based on their omeprazole equivalency.
Authors: G Sachs; J M Shin; K Munson; O Vagin; N Lambrecht; D R Scott; D L Weeks; K Melchers Journal: Aliment Pharmacol Ther Date: 2000-11 Impact factor: 8.171
Authors: Kadir Öztürk; Ömer Kurt; Gürkan Çelebi; Hakan Şarlak; Muhammed Fatih Karakaya; Hakan Demirci; Ali Kılınç; Ahmet Uygun Journal: Turk J Gastroenterol Date: 2020-03 Impact factor: 1.852
Authors: María Caldas; Ángeles Pérez-Aisa; Manuel Castro-Fernández; Luis Bujanda; Alfredo J Lucendo; Luis Rodrigo; Jose M Huguet; Jorge Pérez-Lasala; Javier Molina-Infante; Jesús Barrio; Luis Fernández-Salazar; Ángel Lanas; Mónica Perona; Manuel Domínguez-Cajal; Juan Ortuño; Blas José Gómez-Rodríguez; Pedro Almela; Josep María Botargués; Óscar Núñez; Inés Modolell; Judith Gómez; Rafael Ruiz-Zorrilla; Cristóbal De la Coba; Alain Huerta; Eduardo Iyo; Liliana Pozzati; Rosario Antón; Mercé Barenys; Teresa Angueira; Miguel Fernández-Bermejo; Ana Campillo; Javier Alcedo; Ramón Pajares-Villaroya; Marianela Mego; Fernando Bermejo; José Luis Dominguez-Jiménez; Llúcia Titó; Nuria Fernández; Manuel Pabón-Carrasco; Ángel Cosme; Pilar Mata-Romero; Noelia Alcaide; Inés Ariño; Tommaso Di Maira; Ana Garre; Ignasi Puig; Olga P Nyssen; Francis Megraud; Colm O'Morain; Javier P Gisbert Journal: Antibiotics (Basel) Date: 2020-12-25
Authors: Olga P Nyssen; Angeles Perez-Aisa; Manuel Castro-Fernandez; Rinaldo Pellicano; Jose M Huguet; Luis Rodrigo; Juan Ortuñ; Blas J Gomez-Rodriguez; Ricardo M Pinto; Miguel Areia; Monica Perona; Oscar Nuñez; Marco Romano; Antonietta G Gravina; Liliana Pozzati; Miguel Fernandez-Bermejo; Marino Venerito; Peter Malfertheiner; Luis Fernanadez-Salazar; Antonio Gasbarrini; Dino Vaira; Ignasi Puig; Francis Megraud; Colm O'Morain; Javier P Gisbert Journal: United European Gastroenterol J Date: 2021-02-11 Impact factor: 4.623